Avapro renal disease supplement
This article was originally published in Pharmaceutical Approvals Monthly
Bristol-Myers Squibb and Sanofi-Synthelabo submit an sNDA for Avapro (irbesartan) Aug. 3 based on results of the PRIME study. The trial evaluated use of the angiotensin II receptor antagonist to prevent progression of renal disease in 2,300 patients with hypertension and type 2 diabetes. The sNDA is receiving priority review
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
No device-related close-out letters were released by the US FDA last month.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.